500 related articles for article (PubMed ID: 33513387)
1. Dihydroquinazolines enhance 20S proteasome activity and induce degradation of α-synuclein, an intrinsically disordered protein associated with neurodegeneration.
Fiolek TJ; Magyar CL; Wall TJ; Davies SB; Campbell MV; Savich CJ; Tepe JJ; Mosey RA
Bioorg Med Chem Lett; 2021 Mar; 36():127821. PubMed ID: 33513387
[TBL] [Abstract][Full Text] [Related]
2. Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers.
Fiolek TJ; Keel KL; Tepe JJ
ACS Chem Neurosci; 2021 Apr; 12(8):1438-1448. PubMed ID: 33788542
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Potent 20S Proteasome Activators for the Potential Treatment of α-Synucleinopathies.
Staerz SD; Jones CL; Tepe JJ
J Med Chem; 2022 May; 65(9):6631-6642. PubMed ID: 35476454
[TBL] [Abstract][Full Text] [Related]
4. Syrosingopine Enhances 20S Proteasome Activity and Degradation of α-Synuclein.
Sadahiro Y; Nishimura S; Hitora Y; Tsukamoto S
J Nat Prod; 2024 Mar; 87(3):554-559. PubMed ID: 37938154
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule Modulation of Proteasome Assembly.
Njomen E; Osmulski PA; Jones CL; Gaczynska M; Tepe JJ
Biochemistry; 2018 Jul; 57(28):4214-4224. PubMed ID: 29897236
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins.
Jones CL; Njomen E; Sjögren B; Dexheimer TS; Tepe JJ
ACS Chem Biol; 2017 Sep; 12(9):2240-2247. PubMed ID: 28719185
[TBL] [Abstract][Full Text] [Related]
7. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
Tóth G; Gardai SJ; Zago W; Bertoncini CW; Cremades N; Roy SL; Tambe MA; Rochet JC; Galvagnion C; Skibinski G; Finkbeiner S; Bova M; Regnstrom K; Chiou SS; Johnston J; Callaway K; Anderson JP; Jobling MF; Buell AK; Yednock TA; Knowles TP; Vendruscolo M; Christodoulou J; Dobson CM; Schenk D; McConlogue L
PLoS One; 2014; 9(2):e87133. PubMed ID: 24551051
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
9. Proteasome activation: A novel strategy for targeting undruggable intrinsically disordered proteins.
Yu Q; Wang Z; Tu Y; Cao Y; Zhu H; Shao J; Zhuang R; Zhou Y; Zhang J
Bioorg Chem; 2024 Apr; 145():107217. PubMed ID: 38368657
[TBL] [Abstract][Full Text] [Related]
10. The C-Terminus of the PSMA3 Proteasome Subunit Preferentially Traps Intrinsically Disordered Proteins for Degradation.
Biran A; Myers N; Steinberger S; Adler J; Riutin M; Broennimann K; Reuven N; Shaul Y
Cells; 2022 Oct; 11(20):. PubMed ID: 36291102
[TBL] [Abstract][Full Text] [Related]
11. Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models.
Zhou H; Shao M; Guo B; Li C; Lu Y; Yang X; ShengnanLi ; Li H; Zhu Q; Zhong H; Wang Y; Zhang Z; Lu J; Lee SM
Neurotherapeutics; 2019 Oct; 16(4):1225-1236. PubMed ID: 31313223
[TBL] [Abstract][Full Text] [Related]
12. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
[TBL] [Abstract][Full Text] [Related]
13. Proteasome Activation to Combat Proteotoxicity.
Jones CL; Tepe JJ
Molecules; 2019 Aug; 24(15):. PubMed ID: 31387243
[TBL] [Abstract][Full Text] [Related]
14. The Disordered Landscape of the 20S Proteasome Substrates Reveals Tight Association with Phase Separated Granules.
Myers N; Olender T; Savidor A; Levin Y; Reuven N; Shaul Y
Proteomics; 2018 Nov; 18(21-22):e1800076. PubMed ID: 30039638
[TBL] [Abstract][Full Text] [Related]
15. Membrane interactions of intrinsically disordered proteins: The example of alpha-synuclein.
Das T; Eliezer D
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):879-889. PubMed ID: 31096049
[TBL] [Abstract][Full Text] [Related]
16. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA.
Zhang P; Park HJ; Zhang J; Junn E; Andrews RJ; Velagapudi SP; Abegg D; Vishnu K; Costales MG; Childs-Disney JL; Adibekian A; Moss WN; Mouradian MM; Disney MD
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1457-1467. PubMed ID: 31900363
[TBL] [Abstract][Full Text] [Related]
17. Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration.
Opoku-Nsiah KA; Gestwicki JE
Transl Res; 2018 Aug; 198():48-57. PubMed ID: 30244692
[TBL] [Abstract][Full Text] [Related]
18. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
19. Antagonizing pathological α-synuclein-mediated neurodegeneration by J24335 via the activation of immunoproteasome.
Pan Z; Yu CW; Zhao C; Shao M; Yang X; Liang X; Li H; Lu Y; Ye Q; Chern JW; Lu J; Zhou H; Lee SM
Toxicol Appl Pharmacol; 2023 Dec; 480():116745. PubMed ID: 37931757
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies.
Martinelli AHS; Lopes FC; John EBO; Carlini CR; Ligabue-Braun R
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
